What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions.
about
Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.Can user testing of a clinical trial patient information sheet make it fit-for-purpose?--a randomized controlled trial.Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.Evaluation of an educational program to improve communication with patients about early-phase trial participationA patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study.Description of the types and content of phase 1 clinical trial consent conversations in practiceNegotiating decisions during informed consent for pediatric Phase I oncology trialsPredictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.What advanced cancer patients with limited treatment options know about clinical research: a qualitative study.Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer.Patient-doctor agreement on recall of clinical trial discussion across culturesEnd-of-life care discussions among patients with advanced cancer: a cohort studyGene therapy researchers' assessments of risks and perceptions of risk acceptability in clinical trials.Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control studyPatient, companion, and oncologist agreement regarding information discussed during triadic oncology clinical interactionsDiscussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer.A study of motivations and expectations of patients seen in phase 1 oncology clinics.Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death.Improving end-of-life care for head and neck cancer patients.Moral justification of Phase 1 oncology trials.Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation.Discussing molecular testing in oncology care: Comparing patient and physician information preferences.Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits.Why take part in personalised cancer research? Patients' genetic misconception, genetic responsibility and incomprehension of stratification-an empirical-ethical examination.Discussing prognosis and treatment goals with patients with advanced cancer: A qualitative analysis of oncologists' language.Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study.Palliative care and advance care planning for pancreas and other cancers.Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.'We have to discuss it': cancer patients' advance care planning impressions following educational information about cardiopulmonary resuscitation.Relationships between personal attitudes about death and communication with terminally ill patients: How oncology clinicians grapple with mortality.A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients."Get the Consent"-Nonfinancial Conflict of Interest in Academic Clinical Research.Communicating about phase I trials: objective disclosures are only a first step.Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation.Disclosure of myelodysplastic syndrome diagnosis: improving patients' understanding and experience.The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study.Informed consent for clinical treatment in low-income setting: evaluating the relationship between satisfying consent and extent of recall of consent information.Deliberation and the life cycle of informed consent.Factors associated with patient recall of key information in ambulatory specialty care visits: Results of an innovative methodology.A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy.
P2860
Q33604264-17FC3F5B-3E27-45D9-960C-335FC337C110Q33967348-4356D207-2E62-4CC0-A460-12811C9A1E50Q34251038-4D327AE9-26FE-42D7-9921-17513AADE82CQ35863887-BED8C056-674F-4D4D-A484-A14C18B2C92EQ35870182-25B54E14-5438-4ECE-A344-14B468C95EFBQ36275979-924E325D-51FA-42F7-B09E-A6F05AB14FEBQ36321519-A611BD92-15B1-48F3-8865-D579A6EFB759Q36326389-8F5662B3-D205-4E7C-982B-02452C5A25C1Q36367525-0F203EE4-D474-4A27-9252-E89C8F2C79BEQ36534690-2C1546A1-B0E2-4C9A-9678-45A908D17AF2Q36551625-48FF9DC7-0417-473C-8A47-C9160280BD58Q36739614-05CB4ED0-8F00-4622-AEBC-E9150673CB7DQ36740288-37953F99-67DB-4A02-ABCF-56F7C5C3B7CAQ36941980-6C6E68BD-675F-4660-B620-070F602524BEQ37169207-F0425FD8-EAC0-4E7C-BF34-658AE6E10771Q37169346-987DAF71-EE4E-44D1-ADAB-1D3F40CD59D7Q37417638-60F6E50A-9BD7-4436-B5A8-446A1D098749Q37686819-2EC3B22D-3EB5-4942-A494-10D324412889Q37988564-44181B9B-144C-4013-BC7E-5AFA80FD5AE4Q38210627-6058BA8A-76B9-4518-AC50-9D2A7FA39648Q38700608-F9A98694-8542-4390-839F-70CF104F3C2CQ38763892-5153550B-3D7D-4F62-B251-4AEDCFCFFFBDQ38822094-230E47B1-A011-4BB7-88D9-308AD6A55E11Q38832807-298C569F-EDF8-4C05-8164-98593F01F46CQ38928102-7FE04D8C-E38F-45E7-8F78-A6FCBC9F8AD0Q39166183-16B0EE1D-FC5B-483F-80B8-2FE6CAB5F796Q39433192-DF9A0464-D192-4725-89D5-5FA400EACBABQ40117148-56BD40AC-CA87-484D-B591-5F2062D40AA4Q40996521-3C39D36E-686C-4A08-9594-7F4C8348AF5DQ41164109-0A3F1D08-B736-49FD-BDA3-F693A5B4DE5CQ41626403-5C0AC88C-4FDF-4452-94DC-BFFFF99BF150Q42227756-373895CE-F7DD-4AD9-92A9-AEE6F66A2FD9Q43152781-BB8142AB-FC6D-4EC1-B047-30631046E5AAQ44616007-E6C9EEAC-737B-4960-8FB4-EEC99364FE3AQ45001542-50BA7BB9-F9F6-4E52-B5DD-4A288A4B016AQ46587807-DF7527C0-6B43-47AD-9596-67658563BF92Q47191528-B1242DA8-112E-492D-B32E-0B49A9ED2C12Q48099580-B20BA2DC-35DF-4B1A-AFF3-ADB3CB010A11Q48123603-E43A74F8-C1A2-45DE-A4ED-BC2A6DD5A6F4Q48237995-7634DBE3-D62B-4B5B-B18D-1035E8FF1CE3
P2860
What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
What oncologists believe they ...... of phase I trial discussions.
@en
What oncologists believe they ...... of phase I trial discussions.
@nl
type
label
What oncologists believe they ...... of phase I trial discussions.
@en
What oncologists believe they ...... of phase I trial discussions.
@nl
prefLabel
What oncologists believe they ...... of phase I trial discussions.
@en
What oncologists believe they ...... of phase I trial discussions.
@nl
P2093
P50
P356
P1476
What oncologists believe they ...... of phase I trial discussions.
@en
P2093
Carolyn Langridge
Denis C Talbot
Susan Catt
Valerie Jenkins
P356
10.1200/JCO.2010.30.0814
P407
P577
2010-11-22T00:00:00Z